About
Who We Are
Smart Nanovirus® Limited is a UK-based biotechnology company built on more than four generations of scientific work with oncolytic viruses, a field exploring how certain viruses can naturally recognize and interact with cancer cells.
Since the 1960s, members of the founding family have contributed to the development of Rigvir virus technology, one of the earliest practical applications of oncolytic virology in cancer therapy.
Today, Smart Nanovirus is advancing this legacy into the next stage: transforming decades of virology research into beneficial virus–based biotechnology designed for cancer protection and longevity.
By combining natural biological intelligence with modern biotechnology, we are developing innovative preventive health solutions aimed at helping people stay one step ahead of cancer.
Our approach connects Natural Intelligence — beneficial viruses found in nature — with modern scientific innovation, creating a new category of bio-intelligent longevity technologies.
Mission
Our mission is to promote a forward-thinking and health-conscious society focused on preventing disease rather than waiting for diagnosis.
We believe that informed lifestyle choices, nutrition, and advanced biotechnology can play a key role in long-term health and longevity.
Through our work, we strive to contribute to global efforts aimed at reducing the growing burden of cancer worldwide.
First-in-Class Technology
Within our biotechnology platform, we have already developed two next-generation supplements: RIGVIR SE and RIGVIR X.
Both products contain an adapted live, non-pathogenic and non-genetically modified ECHO-7 Rigvir virus, a unique biological agent studied for its ability to interact with abnormal cells.
With these developments, we are among the first in the world to introduce beneficial virus-based biotechnology into practical use in the preventive health and longevity sector.
Focus
Our current focus is the development of Rigvir virus-based biotechnology in the non-medical segment, where the virus concentration is carefully adapted and combined with other components.
This approach allows the Rigvir virus to be used as part of innovative food supplement solutions designed for long-term preventive health strategies.
Future
The future of Rigvir virus technology lies in its synergy with early cancer detection technologies, digital health solutions, and Artificial Intelligence.
Within the next few years, Rigvir-based biotechnology may help millions of people worldwide whose future cancer risks are predicted through AI-driven diagnostics and advanced screening technologies.
Today, individuals identified as having elevated cancer risk often have limited options beyond monitoring and waiting for a diagnosis.
Our goal is to change that.
We believe that preventive biotechnology can help humanity stay one step ahead of cancer.
Exclusive Rights
The ECHO-7 Rigvir virus is internationally patented.
Smart Nanovirus® Limited has received an exclusive licence for the use of the Rigvir virus and the Rigvir trademark in the development of non-medical products and projects.
Sales & Distribution
Retail sales of Rigvir products are ensured through the official company webstore: www.smartnanovirus.com as well as through authorised webstores and selected healthcare professionals.
Distribution rights in the B2B segment may be granted to partners following a cooperation agreement and partner audit, ensuring responsible and controlled distribution of Rigvir technology.
Team
Our team includes specialists with many years of experience in pharmacy, biotechnology, and research into oncolytic viruses.
What unites us is a shared commitment to innovation and the belief that biotechnology inspired by nature can help create a healthier future.
We want to help build a healthier future by advancing preventive health technologies and making the world a better place for all of us to live.
As the leader of Smart Nanovirus, Jurgis guides the company with a vision for sustainable strategic growth and innovation that can change the global healthcare paradigm. With 20+ years of experience in biotechnology, medicine, and business management, he combines expertise with a dynamic, results-driven approach to steer the company toward long-term success.
Jurgis fosters a strong, honest, and collaborative culture and empowers employees. Under his leadership, Smart Nanovirus consistently develops new, unique, and groundbreaking products while delivering exceptional service and building lasting client relationships.
As Leading Scientist at Smart Nanovirus, Ivars Kalvins, PhD. chem. brings pioneering research and innovation to the company. With decades of experience in medicinal chemistry and drug development, he leads projects that advance global healthcare. He has developed several original medicines in the oncology and cardiology field. He is the developer of multiple original medicines, including Meldonium and Belinostat, and the author of more than 500 scientific publications and over 500 patents and patent applications. Awarded the WIPO Gold Medal for outstanding achievements in innovation.
Prof. Kalvins is committed to pushing boundaries and fostering excellence. His work at Smart Nanovirus focuses on developing new, transformative solutions while strengthening the company’s reputation for impactful, innovative, cutting-edge research.